AI Pathology Tool Aims To Improve Biomarker Scoring

Leica Biosystems and Indica Labs have announced a strategic collaboration with Lunit (KRX:328130.KQ), a provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms.  The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC1 is now available through Leica Biosystems’ Aperio AI Store.

In driving this collaboration, Leica Biosystems will work together with Indica Labs and Lunit to support pharmaceutical partners in integrating AI-enabled digital pathology into routine clinical research.Biomarker scoring remains highly variable, as disease state assessments and treatment decisions often rely on manual evaluation of stained tissue under a microscope. This process can be time-consuming and prone to human variability. By combining Leica Biosystems’ expertise in IHC staining and digital pathology, Indica Labs’ image management platform, and Lunit’s advanced AI analysis, the partnership aims to support consistent scoring approaches, enable robust biomarker analysis, and accelerate research workflows.

The partnership brings together Leica Biosystems’ PD-L1 IHC assay platform1, Aperio GT 450 digital pathology scanner1, Aperio HALO AP image management solution2, and now Lunit SCOPE biomarker scoring algorithm1 to deliver a seamless, AI-powered pathology workflow.

“As a first step, we’re integrating Lunit’s algorithm directly into our image management software powered by Indica Labs, which enables a continuous workflow for users of the Aperio GT 450 scanner,” said Karan Arora, SVP of Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. “This launch aligns with our long-term vision to deliver scalable, seamlessly integrated research workflows to the market.”

This three-way integration reflects a shared commitment to open pathology and interoperability. Indica Labs CEO Steven Hashagen emphasized that “robust end-to-end solutions like these are a critical step toward realizing the promise of AI in digital pathology.”

Brandon Suh, CEO of Lunit, added, “We are encouraged by the strong interest from pharmaceutical partners and excited about the potential this collaboration holds. Together, we’re applying AI to pathology image analysis at unprecedented scale, with a shared goal of delivering precision diagnostics that translate into tangible improvements in patient care.”

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.